Stocks · News reference
Cadrenal Therapeutics Consolidates Multi-Indication Strategy For Cardiac Acute Critical Care Franchise, With Focus On CAD-1005 For Both HIT And CSA-AKI
Urgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent need for novel upstream targets, such as 12-LOX, that are being studied to address the root causes of cardio-renal
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 3, 2026, 12:31 PM
- Checked
- Aug 3, 2026, 12:31 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Cadrenal Therapeutics, Inc. (CVKD)
Filed: 2026-07-21 AccNo: 0001213900-26-079824 Size: 229 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarCadrenal Therapeutics Unveils Cardiac Critical Care Franchise, Seeks Partners For Late-Stage Cardiovascular Assets
Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditionsCompany is exploring development, licensing, and commercialization
Read original at benzinga